The antiviral action of different human interferons against encephalomyocarditis virus in HeLa cell cultures was analyzed. Cell treatment with levamisole (200 ,ug/ml), methisoprinol (1 mg/ml), or adenine or adenosine (33 or 100 ,g/ml, respectively) potentiated the anti-encephalomyocarditis virus activity of human interferon by 8-to 32-fold. A higher level of potentiation (256-fold) was achieved either by combined treatments with levamisole plus methisoprinol or by treatment with one of these compounds plus adenine or adenosine.
The antiviral action of different human interferons against encephalomyocarditis virus in HeLa cell cultures was analyzed. Cell treatment with levamisole (200 ,ug/ml), methisoprinol (1 mg/ml), or adenine or adenosine (33 or 100 ,g/ml, respectively) potentiated the anti-encephalomyocarditis virus activity of human interferon by 8-to 32-fold. A higher level of potentiation (256-fold) was achieved either by combined treatments with levamisole plus methisoprinol or by treatment with one of these compounds plus adenine or adenosine.
Interferons (IFNs) are a group of proteins which influence diverse biological activities, including the inhibition of the replication of many viruses. Among these influences, the blockade of encephalomyocarditis (EMC) virus has been widely documented (3, 9, 12-15, 17, 19) . Treatment of human HeLa cells with IFN induces a transient refractory state in the replication of EMC virus which causes a blockade of viral protein synthesis (12, 13, 15, 19) . The protection of HeLa cell cultures against EMC virus infection depends on the IFN concentration (13, 14) . It is obvious that the potentiation of IFN action would be of great clinical interest. First, this would allow the use of lower IFN doses; second, the undesirable effects of IFN administration would be ameliorated. Thus, several attempts to find synergistic activity between different compounds and IFN have been reported (1, 8, 10, 18) .
Levamisole is an antihelmintic drug of veterinary use, the capability of which to restore depressed immune responsiveness has led to its clinical challenge (16) . The biochemical mode of action of levamisole is still unknown. It has been proposed that levamisole alters the intracellular cyclic nucleotide concentration by increasing the cGMP/cAMP ratio (7) . Methisoprinol (isoprinosine, inosiplex) has been considered to be an antiviral agent. However, it has no direct antiviral effect (5 low multiplicities of infection of EMC virus, a gradual protection against the cytopathic effect and monolayer disruption induced by viral infection was observed, as expected (Fig. 1) . The protective activity of several types of human IFN was enhanced by simultaneous pretreatment of cell cultures with levamisole or methisoprinol at concentrations which did not show any antiviral effect when used alone (200 and 1,000 ,ug/ml, respectively). The level of potentiation was even higher when both compounds were added together (Table 1) . Reproducible results were obtained with both natural human alpha and gamma IFNs and also with recombinant human IFN-a2 and human lymphoblastoid IFN (Table 1), within a twofold factor, probably because of the variability of in vivo cell culture experiments. We also observed that increasing the period of cell pretreatment with levamisole or methisoprinol or both augmented the potentiation. This was maximal (128-fold) when both compounds were added to cells before (24 h) IFN and declined progressively if levamisole was added later. However, a slight enhanced protection was observed even when these compounds were added after virus infection. The effect of cell treatment with the compounds before and after infection was also analyzed. Under these conditions, recombinant IFN-a2 activity was even more potentiated than when compounds were present only before infection (Table 1) .
In the course of a screening of several compounds for their enhancement of the antiviral activity of IFN, we found that adenine and adenosine were also able to stimulate IFN action against EMC virus. In this system, the highest level of potentiation (8- toxic to cell cultures at 300 and 2,000 pug/ml, respectively.
However, combined treatments with levamisole plus methisoprinol showed a low toxicity at lower concentrations (200 and 1,000 ,ug/ml, respectively) which was higher in prolonged treatments, when drugs were replaced after the virus adsorption period. Concentrations of adenine higher than 100 ,ug/ml or concentrations of adenisone higher than 500 ,ug/ml during the assays were also toxic.
According to these results, levamisole and methisoprinol, and more notably a combination of the two, caused a reduction in the production of infective vinons in IFNtreated HeLa cells (Table 2) . Thus, it is clear that these compounds separately increased the inhibitory activity of human IFN against EMC virus.
In summary, our results indicate that levamisole and methisoprinol potentiate, in a dose-dependent manner, the protection against EMC virus infection induced by IFN in human HeLa cells. Interestingly enough, the combination of both levamisole and methisoprinol causes a higher potentiation, suggesting that these compounds probably act at different levels. 
